Lipidoids for nucleic acid transfection and use thereof
A lipidoid is disclosed of general formula I wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The disclosure further describes transfection agents, transfection particles containing this lipidoid, and their use.
1 . Compounds of general formula I
wherein X is selected from a group consisting of —C(═O)NH—, —C(═O)O—, —C(═S)O—, —C(═O)S—, —C(═S)S—, —C(═O)NHNH—, —CH 2 —, —O—, —OC(═O)—, —S—, —SC(═O)—, —NH—, —NHNH—, —NHC(═O)—, —NHNHC(═O)—, —C≡C—, —CH═CH—, a five-membered heterocycle containing at least 2 nitrogen atoms, —CH 2 C(═O)NH—, —CH 2 C(═O)O—, —CH 2 C(═S)O—, —CH 2 C(═S)S—, —CH 2 C(═O)NHNH—, —N═CH—, and —CH═N—;
Y is independently selected from the group consisting of C 2 -C 10 alkylene chains wherein in the alkylene chain, one or more —CH 2 — groups may optionally be replaced with one or more 0 or S atoms;
Z is selected from the group consisting of hydrogen, —OH, —CH 2 OH, —NH 2 , —N + (CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —N + (CH 3 ) 2 —(CH 2 ) 2 —COO—, and —NHCH 3 , —N(CH 3 ) 2 , —N + (CH 3 ) 3 , —OCH 3 , —OCH 2 CH 3 , —C(═O)R 1 ,
wherein R 1 is selected from —NH 2 , —NH(CH 2 ) n OH, —N[(CH 2 ) n OH] 2 , —NHCH(CH 2 OH) 2 , —NHCH 2 CH(—OH)CH 2 OH, —NH(CH 2 ) C(═O)NH 2 , —N[CH 2 C(═O)NH 2 ] 2 , —NHCH[C(═O)NH 2 ] 2 , —NH(CH 2 ) 2 NHC(═O)NH 2 ,
wherein n is an integer within the range from 2 to 5;
and R are the same or different from each other, each R being independently selected from the group consisting of C 8 -C 20 alkyl, C 8 -C 20 alkenyl, and C 8 -C 20 alkynyl, wherein in the alkyl, alkenyl or alkynyl, one or more —CH 2 — groups may optionally be replaced with one or more groups selected from —CH(OH)—, —OC(═O)—, —C(═O)O—, —S—S—, —C(═O)NH—, —NHC(═O)—, —O—, and —S—;
and pharmaceutically acceptable salts, addition salts and solvates thereof.
2 . The compound according to claim 1 , wherein Z is selected from a group consisting of hydrogen, —OH, —CH 2 OH, —NH 2 , —N′(CH 3 ) 2 —(CH 2 ) 3 —SO 3 − , —N + (CH 3 ) 2 —(CH 2 ) 2 —COO—, and —C(═O)R 1 ,
wherein R 1 is selected from —NH 2 , —NH(CH 2 ) n OH, —N[(CH 2 ) n OH] 2 , —NHCH(CH 2 OH) 2 , —NHCH 2 CH(OH)CH 2 OH, —NH(CH 2 ) n C(═O)NH 2 , —N[CH 2 C(═O)NH 2 ] 2 , —NHCH[C(═O)NH 2 ] 2 , —NH(CH 2 ) 2 NHC(═O)NH 2 ,
wherein n is an integer within the range from 2 to 5.
3 . The compound according to claim 1 , wherein X is selected from —C(═O)NH—, a five membered heterocycle containing at least 2 nitrogen atoms, or —C(═O)O—.
4 . The compound according to claim 1 , wherein R is independently selected from the group consisting of C 8 -C 20 alkyl, C 8 -C 20 alkenyl, and C 8 -C 20 alkynyl, wherein in the said alkyl, alkenyl or alkynyl, one or more —CH 2 — groups may optionally be replaced by one or more groups selected from —CH(OH)—, —OC(═O)—, and —C(═O)O—.
5 . The compound according to claim 1 , wherein all R in the molecule are the same, or all nitrogen atoms in the molecule are substituted identically by two identical R or two different R.
6 . A transfection agent comprising at least one compound of general formula I according to claim 1 in an amount of 10 to 50 mol. %, and at least one helper lipid in a total amount of 50 to 90 mol. %.
7 . A transfection agent comprising at least one compound of general formula I according to claim 1 in an amount of 15 to 30 mol. %, cholesterol in an amount of 30 to 55 mol. %, and at least one further helper lipid in an amount of 20 to 50 mol. %.
8 . A transfection particle comprising at least one compound of general formula I according to claim 1 , at least one nucleic acid and/or a part thereof and/or nucleic acid derivative, and at least one helper lipid.
9 . A method of treatment comprising the step of administering the compound of general formula I according to claim 1 for in vitro transfection of cells or tissues with nucleic acid and/or a part thereof and/or nucleic acid derivative to a subject in need thereof.
10 . The method of treatment according to claim 9 for silencing or activating at least one chromosomal gene(s), silencing or activating immunogens, inhibiting or activating signaling pathways, editing genome or transcriptome, or enabling the expression of at least one protein(s) encoded by the nucleic acid.
11 . The compound of general formula I according to claim 1 for transfecting cells or tissues with nucleic acid and/or a part thereof and/or nucleic acid derivative in vivo, preferably except for the transfection of human embryos for industrial or commercial purposes and except for the modification of a human germ line.
12 . The compound of general formula I according to claim 1 for silencing or activating chromosomal genes(s), silencing or activating immunogens, inhibiting or activating signaling pathways, editing genome or transcriptome, or enabling the expression of the protein(s) encoded by the nucleic acid.
13 . A method of administering a medicament, comprising the step of administering the compound of general formula I according to claim 1 for gene therapy.
14 . A method of treatment of administering the compound of general formula I according to claim 1 in cosmetic preparations for delivering an active ingredient to the site of action to a subject in need thereof.